Minirin (Desmopressin Acetate)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney's collecting ducts. This triggers a cascade that inserts aquaporin‑2 channels into the cell surface, allowing more water to be reabsorbed, thereby concentrating urine and reducing urine volume. The same receptor activation also promotes release of clotting factors from endothelial cells.

The appropriate dose of Minirin is determined by the prescribing clinician based on the individual’s condition, age, weight, and response to therapy. Dosage may vary for central diabetes insipidus, nocturnal enuresis, or hemophilia A, and adjustments are made according to clinical monitoring.

Safety data for Minirin in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when possible. If treatment is deemed necessary, it should be closely supervised with appropriate monitoring of the mother and fetus or infant.

To request Minirin, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue with a longer half‑life and greater selectivity for V2 receptors, resulting in fewer cardiovascular side effects compared with natural vasopressin, which also stimulates V1 receptors causing vasoconstriction. Consequently, desmopressin is preferred for antidiuretic and haemostatic indications.

Minirin nasal spray should be stored at temperatures below 25 °C, protected from moisture and direct sunlight. Keep the product in its original packaging until use, and discard any spray that appears discolored or has been opened beyond the labeled period after opening.

Minirin is supplied as a metered‑dose nasal spray. The prescribed number of sprays is delivered into one nostril, typically once or twice daily, depending on the indication. Patients should avoid blowing their nose immediately after administration and follow the prescriber’s instructions for timing and dosing.

The most serious risks include severe hyponatraemia, which can lead to seizures, coma, or death, and water intoxication from excessive fluid retention. Patients should be monitored for rapid weight gain, low sodium levels, and neurological symptoms, especially when combined with other antidiuretic agents.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin, uncontrolled hyponatraemia, severe renal impairment, or those taking other potent antidiuretic medications without medical supervision. Caution is also advised for individuals with a history of epilepsy, heart failure, or uncontrolled hypertension.